VIENNALAB - Established innovations in diagnostics

Non-small cell lung cancers (NSCLC) comprise approximately 85% of all lung cancers. Somatic mutations in the epidermal growth factor receptor tyrosine kinase (EGFR-TK) domain influence the treatment with EGFR-TK inhibitors. The EGFR StripAssay® identifies the most important mutations relevant for anti EGFR-TK therapy

EGFR StripAssay®

  • TK inhibitors, such as erlotinib and gefitinib, are effective anti-cancer drugs in NSCLC patients carrying activating EGFR mutations
  • Conversely, patients carrying the resistance mutation p.T790M do not benefit from EGFR-TK inhibitor therapy.
  • Identification of EGFR mutations allows the decision whether an EGFR-TK inhibitor or standard chemotherapy is the optimal first-line treatment.

Product Details

EGFR XL StripAssay® ref5-630